CAS: 1193383-09-3

JNJ-42041935

Applications JNJ 42041935 is a selective hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) enzyme inhibitor. It can potentially be used for the treatment of inflammation-induced anemia. References Barrett, T., et al.: Mol. Pharmacol., 79, 910 (2011); Thirstrup, K., et al.: Pharmacol. Res., 64, 268 (2011);

JNJ-42041935 (HIF-PHD Inhibitor II) is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes.

1-(6-Chloro-5-(Trifluoromethoxy)-1H-Benzo[D]Imidazol-2-Yl)-1H-Pyrazole-4-Carboxylic Acid

JNJ 42041935 is a pharmacologic agent that inhibits the growth of cancer cells and may be used to treat chronic kidney disease. This drug binds to the extracellular matrix, which prevents the proliferation of cells in the tissue. JNJ 42041935 has been shown to inhibit the production of messenger RNA in urine samples taken from patients with chronic kidney disease. The clinical studies have shown that JNJ 42041935 can reduce the incidence of leukemia and blood disorders. The effective dose for this drug is not yet known, but it is thought that it may be around 1-10 mg/kg daily. It is also unknown how long JNJ 42041935 will remain in the body or what its excretion rate is.